<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122872">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140372</url>
  </required_header>
  <id_info>
    <org_study_id>S13-00747</org_study_id>
    <nct_id>NCT02140372</nct_id>
  </id_info>
  <brief_title>Anti-platelet Effects of Colchicine</brief_title>
  <official_title>Anti-platelet Effects of Colchicine in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour
      later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug
      administration, 2 hours after colchicine administration, and 24 hours after colchicine
      administration via the antecubital vein and evaluated for markers of platelet activity and
      inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>monocyte platelet aggregate</measure>
    <time_frame>change from baseline pre-drug to 2 hour post-drug</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>leukocyte platelet aggregation</measure>
    <time_frame>change from baseline pre-drug to 2 hours post-drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>light transmission aggregometry</measure>
    <time_frame>change from baseline pre-drug to 2 hours post-drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-selectin</measure>
    <time_frame>change from baseline pre-drug to 2 hours post-drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet adhesion</measure>
    <time_frame>change from baseline pre-drug to 2 hours post-drug</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Volunteer group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <arm_group_label>Volunteer group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be more than 18 years of age

        Exclusion Criteria:

        1) history of cardiovascular disease, including myocardial infarction, history of
        percutaneous coronary angioplasty or stent, peripheral vascular disease or stroke; 2)
        history of myelodysplasia; 3) medications known to affect platelet function, including
        non-steroidal anti-inflammatory drugs, antihistamines, and selective serotonin reuptake
        inhibitors, during the 5 days prior to participation; 4) medications known to interact
        with colchicine; 5) history of intolerance to colchicine; 6) acute or chronic symptoms of
        diarrhea, nausea, or vomiting within 1 month prior to enrollment; 7) known anemia or
        hemoglobin &lt;10mg/dL; 8) platelet count &lt;100,000 or &gt; 450,000; 9) creatinine clearance
        &lt;30cc/minute; 10) any known hemorrhagic diathesis; 11) pregnant; 12) Unable to consent; or
        13) Participating in a competing study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binita Shah, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU SOM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhisham Harchandani</last_name>
    <phone>212-263-4194</phone>
    <email>bhisham.harchandani@nyumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colchicine</keyword>
  <keyword>platelet activity</keyword>
  <keyword>neutrophil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
